LINC00887 Fosters Development of Clear Cell Renal Cell Carcinoma via Inhibiting CD8+ T Cell Immune Infiltration

Background lncRNAs affect adaptive and innate immunity of cancer via mediating functional states of immune cells, genes, and pathways. Nonetheless, little is known about the molecular mechanism of lncRNA-mediated CD8+ T cell immune infiltration in progression of clear cell renal cell carcinoma (ccRCC). We designed this work to investigate the role of LINC00887 in regulating CD8+ T cell immune infiltration in ccRCC. Methods Correlation between LINC00887 and immune factors and the expression level of LINC00887 in ccRCC were analyzed by bioinformatics methods (TCGA-KIRC database, “edgeR” package, “clusterProfiler” package, and “CIBERSORT” package). LINC00887 expression in ccRCC was examined via RT-qPCR. The cytokilling capacity of CD8+ T cells was evaluated by the lactate dehydrogenase assay. The apoptotic ability of CD8+ T cells was measured by flow cytometry. The chemotactic ability of CD8+ T cells was revealed by chemotaxis assay. CXCR3, CXCL9, and CXCL10 levels were assessed by RT-qPCR. Results As suggested by bioinformatics analysis, LINC00887 was markedly upregulated in ccRCC patients and associated with expression of immune-suppression molecule, thereby abating the immune infiltration level of CD8+ cells in tumor tissue. As revealed by cellular assay, LINC00887 was upregulated in ccRCC cells, and knockdown of LINC00887 resulted in a decreased PD-L1 expression, increased CD8+ T cell toxicity, decreased apoptotic levels, and enhanced chemotaxis. Moreover, we found that LINC00887 exhibited inhibitory effect on immune infiltration of CD8+ cells in clinical tissues. Conclusions The results of this study suggested that LINC00887 promoted ccRCC progression by inhibiting immune infiltration of CD8+ T cells, providing new insights into pathogenesis of ccRCC and suggesting LINC00887 being a promising immunotherapy target for ccRCC.

[1]  L. Qin,et al.  GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages , 2021, Signal Transduction and Targeted Therapy.

[2]  S. Salek-Ardakani,et al.  CD8+ T Cell Exhaustion in Cancer , 2021, Frontiers in Immunology.

[3]  Ming-Rong Zhang,et al.  Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy , 2021, Journal for ImmunoTherapy of Cancer.

[4]  Qiang Sun,et al.  SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis , 2021, Frontiers in Oncology.

[5]  Zhenlin Yang,et al.  LINC00152 mediates CD8+ T-cell infiltration in gastric cancer through binding to EZH2 and regulating the CXCL9, 10/CXCR3 axis , 2021, Journal of Molecular Histology.

[6]  Yang Jiang,et al.  Pan-Cancer Analysis of NOS3 Identifies Its Expression and Clinical Relevance in Gastric Cancer , 2021, Frontiers in Oncology.

[7]  J. Larkin,et al.  Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Liu,et al.  LINC00887 aggravates the malignant progression of glioma via upregulating CCND1. , 2021, European review for medical and pharmacological sciences.

[9]  Pei Li,et al.  Linc00887 suppresses tumorigenesis of cervical cancer through regulating the miR-454-3p/FRMD6-Hippo axis , 2021, Cancer cell international.

[10]  Xu Zhang,et al.  DMDRMR-Mediated Regulation of m6A-Modified CDK4 by m6A Reader IGF2BP3 Drives ccRCC Progression , 2020, Cancer Research.

[11]  R. Xu,et al.  LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer , 2020, Cancer communications.

[12]  P. Hegde,et al.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. , 2020, Cancer cell.

[13]  ping wang,et al.  MiR-125b-2-3p associates with prognosis of ccRCC through promoting tumor metastasis via targeting EGR1. , 2020, American journal of translational research.

[14]  Y. Wang,et al.  LINC00887 regulates the proliferation of nasopharyngeal carcinoma via targeting miRNA-203b-3p to upregulate NUP205. , 2020, European review for medical and pharmacological sciences.

[15]  Biao Zhang,et al.  LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1 , 2020, Cancer Cell International.

[16]  Hui Zhang,et al.  LINC00973 is involved in cancer immune suppression through positive regulation of Siglec‐15 in clear‐cell renal cell carcinoma , 2020, Cancer science.

[17]  Yanlv Ren,et al.  LncRNA GATA3‐AS1 facilitates tumour progression and immune escape in triple‐negative breast cancer through destabilization of GATA3 but stabilization of PD‐L1 , 2020, Cell proliferation.

[18]  Y. Zhong,et al.  Serum long non‐coding RNA LINC00887 as a potential biomarker for diagnosis of renal cell carcinoma , 2020, FEBS open bio.

[19]  W. Rathmell,et al.  PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma , 2020, Nature Communications.

[20]  Yangchun Xie,et al.  LncRNA NEAT1 Interacted With DNMT1 to Regulate Malignant Phenotype of Cancer Cell and Cytotoxic T Cell Infiltration via Epigenetic Inhibition of p53, cGAS, and STING in Lung Cancer , 2020, Frontiers in Genetics.

[21]  Jing Ma,et al.  Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC , 2020, Diagnostic Pathology.

[22]  Zhao-yun Li,et al.  lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer , 2020, Breast Cancer.

[23]  Lihui Wang,et al.  LncRNA-LET inhibits cell growth of clear cell renal cell carcinoma by regulating miR-373-3p , 2019, Cancer Cell International.

[24]  M. Hung,et al.  Mechanisms Controlling PD-L1 Expression in Cancer. , 2019, Molecular cell.

[25]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[26]  Zhigui Li,et al.  PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway , 2019, Cell proliferation.

[27]  Aimin Jiang,et al.  Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment , 2018, Front. Immunol..

[28]  Li Jiang,et al.  LncRNA-MM2P Identified as a Modulator of Macrophage M2 Polarization , 2018, Cancer Immunology Research.

[29]  G. Burness,et al.  50 years of comparative biochemistry: The legacy of Peter Hochachka. , 2018, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[30]  H. Yao,et al.  NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death , 2018, Nature Immunology.

[31]  H. Moch,et al.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. , 2016, European urology.

[32]  Obi L. Griffith,et al.  GenVisR: Genomic Visualizations in R , 2016, bioRxiv.

[33]  Bin Zhang,et al.  Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma , 2015, Oncotarget.

[34]  James A. Heward,et al.  Long non-coding RNAs in the regulation of the immune response , 2014, Trends in Immunology.

[35]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..